权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel injectable analgesic delivery system for musculoskeletal pain management

用于肌肉骨骼疼痛管理的新型注射镇痛输送系统

基本信息

批准号：
10657572
负责人：
Lakshmi S Nair
金额：
$ 36.03万
依托单位：
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-01 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10657572
关键词：
Absence of pain sensation Acute Address Adrenal Cortex Hormones American Analgesics Anesthetics Animal Model Anti-Inflammatory Agents Attention Attenuated Behavioral Biocompatible Materials CCL4 gene Cell Line Cells Cessation of life Clinical Clinical Data Combined Modality Therapy Curcumin Degenerative polyarthritis Dexamethasone Diffusion Dose Drug Combinations Drug Delivery Systems Drug usage Effectiveness Electrophysiology (science)Engineering Epidemic Flare Formulation Future Goals Health Care Costs Hydrogels Hyperalgesia Impairment In Vitro Inflammation Injectable Injections Injury Intervention Knee LOX gene Ligation Lipids Local Anesthetics Low Back Pain Macrophage Mechanics Mediator Methylprednisolone Modeling Musculoskeletal Musculoskeletal Pain Musculoskeletal System Nerve Nerve Block Neuralgia Neuroglia Neurons Nociception Operative Surgical Procedures Opiate Addiction Opioid Opioid Rotation Oral Overdose Pain Pain intensity Pain management Patients Pharmaceutical Preparations Postoperative Period Process Proliferating Property Quality of life Rattus Research Resolution Schwann Cells Shoulder Signal Transduction Site Spinal Ganglia Testing United States analog attenuation behavioral response clinical pain compliance behavior controlled release efficacy evaluation experience improved in vitro Model in vivo in vivo Model inhibitor laurencin lipoxin A4 mechanical allodynia nanocapsule nanocomposite neuroprotection neurotoxicity novel opioid abuse opioid therapy opioid use outpatient facility pain model pain relief painful neuropathy perineural pre-clinical prescription opioid prevent response ropivacaine safety assessment sciatic nerve side effect synergism

项目摘要

Project Summary Acute flare-ups of musculoskeletal conditions (i.e., post-operative hyperalgesia, osteoarthritis, occipital neuralgia, and lower back pain) present as increased intensity of pain. Currently, opioids are prescribed to treat these flare- ups, making musculoskeletal pain one of the most frequent reasons for opioid prescriptions. Overdoses, abuses, diversions, and deaths from prescription opioids have reached epidemic proportions in the United States with associated healthcare costs of over $700 billion. Our long-term objective is to develop alternative, non-addictive interventions to treat flare-ups of musculoskeletal conditions. Our proposed research aims to develop injectable long-acting anesthetic formulations by combining local anesthetics with low doses of anti-inflammatory/analgesic pain modulators and sustained delivery of these drugs using engineered carriers. Preliminary studies showed the potential of synergistic drug combinations in conjunction with injectable hydrogel/lipid nanocapsule nanocomposites in prolonging local analgesia. We propose to evaluate clinically used corticosteroids as well as emerging analgesic pain modulators in conjunction with ropivacaine to identify the synergistic drug combinations. A diffusion- and degradation-controlled release process will be investigated for the sustained delivery of the analgesic pain modulators to prevent perineural inflammation and neurotoxicity. The in vivo assessment of the efficacy and safety of the formulations will be performed by following the behavioral and electrophysiological responses in rat models. An injectable long-acting formulation, which can be administered in an outpatient facility and can sustain local hypoalgesic effects for 7-14 days, would significantly enhance the quality of life for those suffering from flare-ups without the dire consequences of opioid therapy.

项目总结